| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 921 | 2022 |
| Mapping the human genetic architecture of COVID-19 MEK Niemi, J Karjalainen, RG Liao, BM Neale, M Daly, A Ganna, ... Nature 600 (7889), 472-477, 2021 | 739* | 2021 |
| Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 294 | 2021 |
| Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study RK Gupta, EM Harrison, A Ho, AB Docherty, SR Knight, M van Smeden, ... The Lancet Respiratory Medicine 9 (4), 349-359, 2021 | 211 | 2021 |
| Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the … CI Bloom, TM Drake, AB Docherty, BJ Lipworth, SL Johnston, ... The lancet Respiratory medicine 9 (7), 699-711, 2021 | 168 | 2021 |
| A prenylated dsRNA sensor protects against severe COVID-19 A Wickenhagen, E Sugrue, S Lytras, S Kuchi, M Noerenberg, ML Turnbull, ... Science, eabj3624, 2021 | 150 | 2021 |
| Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study TM Drake, AM Riad, CJ Fairfield, C Egan, SR Knight, R Pius, ... The Lancet 398 (10296), 223-237, 2021 | 147 | 2021 |
| Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK AB Docherty, RH Mulholland, NI Lone, CP Cheyne, D De Angelis, ... The Lancet Respiratory Medicine 9 (7), 773-785, 2021 | 99 | 2021 |
| Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study TM Drake, CJ Fairfield, R Pius, SR Knight, L Norman, M Girvan, ... The Lancet Rheumatology 3 (7), e498-e506, 2021 | 87 | 2021 |
| SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ... EBioMedicine 87, 2023 | 71 | 2023 |
| The impact of viral mutations on recognition by SARS-CoV-2 specific T cells TI de Silva, G Liu, BB Lindsey, D Dong, SC Moore, NS Hsu, D Shah, ... Iscience 24 (11), 2021 | 62 | 2021 |
| Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study F Närhi, SR Moonesinghe, SD Shenkin, TM Drake, RH Mulholland, ... The Lancet Digital Health 4 (4), e220-e234, 2022 | 29 | 2022 |
| Safety perspectives on presently considered drugs for the treatment of COVID‐19 SL Penman, RT Kiy, RL Jensen, C Beoku‐Betts, A Alfirevic, D Back, ... British Journal of Pharmacology 177 (19), 4353-4374, 2020 | 21 | 2020 |
| International pediatric COVID-19 severity over the course of the pandemic Y Zhu, FJ Almeida, JK Baillie, AC Bowen, PN Britton, ME Brizuela, ... JAMA pediatrics 177 (10), 1073-1084, 2023 | 10 | 2023 |
| Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with … BJ Heaton, RL Jensen, J Line, CAW David, DE Brain, AE Chadwick, ... Biomedicine & Pharmacotherapy 150, 112999, 2022 | 6 | 2022 |
| Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19 JK Sidhu, MK Siggins, F Liew, CD Russell, ASS Uruchurtu, C Davis, ... The Journal of infectious diseases, jiad590, 2023 | 1 | 2023 |
| Greater mechanistic understanding of the cutaneous pathogenesis of Stevens–Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a … ED Ogiji, N Aboheimed, K Ross, C Voller, R Siner, RL Jensen, CE Jolly, ... Current Opinion in Allergy and Clinical Immunology, 10.1097, 2024 | | 2024 |
| Glycolysis: An early marker for vancomycin‐specific T‐cell activation J Gardner, S Hammond, R Jensen, A Gibson, MS Krantz, M Ardern‐Jones, ... Clinical & Experimental Allergy 54 (1), 21-33, 2024 | | 2024 |
| Clinical consequences of drug-induced mitochondrial dysfunction RL Jensen, RT Kiy, FFB Dayel, AE Chadwick Mitochondrial Intoxication, 77-100, 2023 | | 2023 |
| SOC-IV-08 Defining the importance of the mitochondrial genome in the role of NAFLD using 3D in vitro transmitochondrial cybrid steatotic and fibrotic models R Jensen, A Chadwick, P Sharma, D Williams Toxicology Letters 368, S54, 2022 | | 2022 |
